Hims & Hers shares jump as FDA begins review of restricted peptide compounds

Proactive

Thu, April 16, 2026 astatine 12:12 PM CDT 2 min read

Shares of Hims & Hers Health (NYSE:HIMS) rose much than 8% to astir $26 aft the US Food and Drug Administration (FDA) moved to statesman a ceremonial reappraisal process that could yet reshape the regulatory presumption of respective wellness peptides utilized successful compounding pharmacies.

The FDA announced it volition clasp meetings connected July 23 and 24 with its Pharmacy Compounding Advisory Committee to sermon whether aggregate peptide-related bulk cause substances should beryllium considered for imaginable inclusion connected the 503A bulks list. The substances nether reappraisal see BPC-157 KPV, TB-500, MOTs-C, emideltide, semax, and epitalon. The bureau besides opened a nationalist remark docket up of the meetings, with submissions owed successful aboriginal July.

Following the announcement, Bank of America raised its terms nonsubjective for Hims & Hers Health to $25 from $21, portion maintaining a ‘Neutral’ rating, pointing to higher adjacent valuation multiples and accrued semipermanent optionality tied to emerging peptide-related developments.

The steadfast besides lifted its people aggregate from astir 21.5x to astir 25.5x, reflecting some broader assemblage re-rating and imaginable strategical upside.

The analysts spot the determination arsenic incrementally constructive for semipermanent optionality but not a near-term net driver. The reappraisal process could, successful theory, grow imaginable compounding pathways and make caller categories of addressable demand, though the eventual result remains uncertain.

In particular, it remains unclear whether cardinal wellness peptides volition yet beryllium permitted for compounding oregon broader commercialization, with the presumption that “It is inactive unclear whether cardinal wellness peptides volition beryllium allowed for compounding oregon wide marketing.”

The aforesaid investigation frames the improvement arsenic an early-stage procedural measurement alternatively than a regulatory unlock.

“This is an archetypal measurement successful the valuation process and not a commercialized unlock of the opportunity,” the analysts wrote, underscoring that immoderate meaningful interaction would beryllium connected aboriginal FDA decisions pursuing the committee reappraisal process.

While the announcement does not alteration existent restrictions, it is seen arsenic adding strategical optionality for companies with vulnerability to compounding infrastructure.

For Hims & Hers, this includes the possibility, if aboriginal rulings are favorable, of repurposing portions of its existing capableness tied to GLP-1-related operations toward different peptide-based offerings, perchance helping offset fixed costs already embedded successful operating assumptions.